Article
Endocrinology & Metabolism
Lei Zheng, Yalong Gu, Jiangcun Silang, Jinlong Wang, Feng Luo, Baopeng Zhang, Chuanhong Li, Feng Wang
Summary: This study successfully constructed nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) of patients with malignant PPGL. The nomograms were found to be accurate and reliable in predicting patient outcomes, providing valuable information for personalized clinical management.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Caihong Zheng, Chengbin Fu, Yahui Wen, Jiameng Liu, Shunguo Lin, Hui Han, Zhonghua Han, Chunsen Xu
Summary: A nomogram was developed and validated to predict the overall survival of patients with metaplastic breast cancer (MBC). MBC patients had worse clinical prognosis compared to infiltrating ductal carcinoma. This nomogram can assist clinicians in making more accurate individualized survival analyses.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jiayi Li, Dongyan Cao
Summary: We developed two prognostic nomograms for predicting recurrence and long-term survival in patients with ovarian clear cell carcinoma (OCCC) after primary treatment, and validated them in patients from the same center. This tool, which uses variables specifically related to OCCC, was more accurate than the FIGO system, making it relatively easy to use in clinic for patient counseling, postoperative management, and follow-up for individual patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biology
Zhongyi Yan, Qiang Wang, Susu Zhao, Longxiang Xie, Lu Zhang, Yali Han, Baokun Zhang, Huimin Li, Xiangqian Guo
Summary: The study aims to build a free prognostic web server for ovarian cancer by integrating gene expression profiles and clinical follow-up information. The constructed web server provides various analysis tools and validates a significant number of prognostic biomarkers. It is a valuable and free web server for prognostic assessment of ovarian cancer.
Article
Obstetrics & Gynecology
Ling Luo, Ningze Xu, Yuyang Liu, Sen Zhong, Sheng Yang, Xi Chen
Summary: This study aimed to identify prognostic factors and develop predictive models for ovarian cancer patients with bone metastasis. The developed nomograms showed good performance in survival prediction and can be used for clinical decision making.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2023)
Article
Oncology
Zhuolin Li, Yao Lin, Bizhen Cheng, Qiaoxin Zhang, Yingmu Cai
Summary: This study evaluated prognostic factors for cervical squamous cell carcinoma (CSCC) and developed personalized risk assessment nomograms to predict overall survival (OS) and cancer-specific survival (CSS) in CSCC patients. The nomograms showed good performance in prognostic prediction and could be used as an effective tool for evaluating the prognosis of CSCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Linlin Chen, Yu Chen, Haoting Shi, Rong Cai
Summary: This study developed and validated nomogram models for predicting overall survival (OS) and cancer-specific survival (CSS) in patients with cervical adenocarcinoma. These models demonstrated excellent performance in prognostic prediction, aiding clinicians in assessing prognosis and tailoring treatments for CA patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Fang Ren, Shengtan Wang, Feifei Li, Jian Gao, Haoya Xu, Xianli Li, Liancheng Zhu
Summary: This study aimed to construct nomograms using data from the SEER database to predict overall survival and cancer-specific survival of ovarian carcinosarcoma (OCS) patients. The nomograms based on independent prognostic factors showed good predictive power and clinical practicality, outperforming traditional staging and grading systems. They enable personalized evaluation of OS and CSS, guiding treatment decisions.
Article
Medicine, General & Internal
Xuan Wei, Wencheng Hu, Kexi Mao
Summary: This study successfully established a DNA methylation-associated predictive model using bioinformatics approaches, which can effectively predict overall survival in patients with stage III to IV ovarian cancer. In addition, a diagnostic nomogram based on the methylation risk score and several clinical variables was developed, and the results showed a high predictive ability of the nomogram.
Article
Oncology
Yawen Zheng, Fang Wang, Wenxia Zhang, Yongmei Li, Bo Yang, Xingsheng Yang, Taotao Dong
Summary: A Vit-based deep learning model was developed to predict overall survival in high-grade serous ovarian cancer patients using preoperative CT images. The model showed promising results and an independent prognostic risk score was established. The study highlights the importance of non-invasive methods for predicting survival in HGSOC and their potential impact on clinical decision making in the era of personalized medicine.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xiangyu Zhang, Yanpeng Hu, Kai Deng, Wanbo Ren, Jie Zhang, Cuicui Liu, Baoqing Ma
Summary: A novel nomogram was developed to predict overall survival (OS) and cancer-specific survival (CSS) for patients with synchronous multiple primary colorectal cancer (SMPCC) using data from the SEER database. The nomogram showed good stability and reliability, and provided a more significant clinical net benefit compared to the TNM staging system.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Qiang Ji, Jun Tang, Shulian Li, Junjie Chen
Summary: This study used data from the National Cancer Institute database to investigate the prognosis of patients with superficial spreading melanoma (SSM) and developed a predictive nomogram. The nomogram showed superior predictive accuracy in determining the overall survival (OS) and cancer-specific survival (CSS) of SSM patients at 1, 3, and 5 years.
Article
Immunology
Yueyi Li, Hang Wang, Ming Chen, Xuelei Ma
Summary: This study identified and validated five immune subtypes associated with different clinical outcomes of platinum-based adjuvant therapy in ovarian cancer patients. The combination of immune subtypes and chemotherapy has the potential to optimize the treatment strategy for OC patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Qian-Kun Yang, Qing-Yuan Lai, Yi Wang, Yang Wang, Zhong-Xiang Yao, Xiao-Jing Zhang
Summary: This study developed and validated nomograms predicting survival of osteosarcoma patients, demonstrating their high accuracy in predicting 3- and 5-year survival rates. The results indicate that nomograms based on the SEER database are reliable tools for survival prediction in osteosarcoma patients.
Article
Reproductive Biology
Li Yang, Jinfen Yu, Shuang Zhang, Yisi Shan, Yajun Li, Liugang Xu, Jinhu Zhang, Jianya Zhang
Summary: This study constructed and validated nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) in patients with ovarian mucinous adenocarcinoma. The nomograms provide accurate predictions for clinicians to assess the prognosis and make treatment plans for patients.
JOURNAL OF OVARIAN RESEARCH
(2022)
Review
Oncology
Katrin M. Sjoquist, Andrew Martin, Nick Pavlakis, David Goldstein, Eric Tsobanis, Daniel Moses, Richard Maher, Wendy Hague, Val Gebski, Martin R. Stockler, R. John Simes
Summary: This study assessed the value of central review in evaluating PFS times in phase 2 clinical trials and found that it supported the reliability of trial results and conclusions.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio Gonzalez-Martin, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Summary: Maintenance therapy with olaparib showed sustained progression-free survival benefit in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. After a 7-year follow-up, there was a clinically meaningful improvement in overall survival. The incidence of myelodysplastic syndrome and acute myeloid leukemia was low.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Azam Majidi, Renhua Na, Susan J. Jordan, Anna DeFazio, Andreas Obermair, Michael Friedlander, Peter Grant, Penelope M. Webb
Summary: This study investigated the association between nonsteroidal antiinflammatory drug (NSAID) use and 5-year cancer-specific survival in Australian women with ovarian cancer. The results showed that frequent use of NSAIDs, including aspirin and nonaspirin NSAIDs, was associated with better survival compared to nonusers and infrequent users. These findings suggest that NSAID use might improve ovarian cancer survival.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Obstetrics & Gynecology
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio Gonzalez-Martin, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Summary: Due to nonspecific symptoms and inadequate screening, ovarian cancer is often diagnosed at an advanced stage, resulting in low survival rates. The PARP inhibitor olaparib has shown significant benefits in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. The SOLO1/GOG 3004 study found that olaparib treatment resulted in prolonged progression-free survival up to 2 years and showed potential overall survival benefits up to 7 years. However, further analysis is needed to confirm the statistical significance.
OBSTETRICAL & GYNECOLOGICAL SURVEY
(2023)
Article
Oncology
Deborah Smith, Kristy P. Robledo, Sonia Yip, Michelle M. Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda Mileshkin, Yoland Antill
Summary: Until recently, the outcome for women with advanced endometrial carcinoma has been poor. New immune therapies have improved outcomes for some women, but determining which women will respond is important. This study aimed to find markers to better predict response to immunotherapy. Tumor-associated inflammatory cells were found to have the strongest association with response. A novel algorithm using optimal cutoff points was able to identify non-responders with high sensitivity. Further validation is needed.
Article
Oncology
Neville F. Hacker, Ellen L. Barlow, Glenn McNally, Stephen Morrell, Val Gebski, Andreas Obermair
Summary: Vulvar cancer is a rare disease that often leads to body image issues due to its treatment. Chronic lower limb lymphedema is a common problem after the removal of groin lymph nodes. The status of these nodes is crucial for prognosis, and most patients require groin dissection. A pilot study on 32 patients showed promising results for serial ultrasonography as a potential alternative to groin dissection in selected patients. The study achieved a high sensitivity and specificity in detecting positive nodes, supporting the need for further research on this approach.
Article
Oncology
Antonio Gonzalez-Martin, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C. McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andres Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O'Cearbhaill, Izabela A. Malinowska, Luda Shtessel, Natalie Compton, Mansoor R. Mirza, Bradley J. Monk
Summary: This study reports the long-term efficacy and safety of the PRIMA/ENGOT-OV26/GOG-3012 trial. The results show that niraparib maintains clinically significant improvements in progression-free survival (PFS) in high-risk patients with newly diagnosed advanced ovarian cancer, regardless of HRD status. No new safety signals were identified.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Bradley J. Monk, Antonio Gonzalez-Martin, Lynn Buckley, Ursula A. Matulonis, B. J. Rimel, Xiaohua Wu, Kathleen N. Moore, Mansoor R. Mirza
Summary: Niraparib, a PARP inhibitor, has shown significant improvement in progression-free survival for advanced epithelial ovarian cancer patients regardless of biomarker status. This review focuses on managing the adverse events associated with niraparib to maintain its efficacy and improve patients’ quality of life. Hematologic events, such as thrombocytopenia, anemia, and neutropenia, were the most commonly reported adverse events, while gastrointestinal events were generally low grade. Clinical strategies including cognitive behavioral therapy and pharmacologic agents are summarized for managing these events. Personalized starting dose of niraparib based on body weight and platelet count demonstrated improved safety profile. Long term safety data from NOVA trial confirmed that niraparib is well tolerated with appropriate and early dose modifications.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Review
Oncology
Ainhoa Madariaga, Rodrigo Sanchez-Bayona, Fernanda G. Herrera, Pedro T. Ramirez, Antonio Gonzalez Martin
Summary: Drug development plays a crucial role in improving outcomes for patients with gynecologic cancers. Clinical trials should measure whether new interventions result in clinically relevant improvements compared to standard care, using reproducible and appropriate endpoints. Overall survival and quality of life are the gold standards for measuring the benefits of new therapeutic strategies. Alternative endpoints, such as progression-free survival, provide early insights into the effects of new drugs but their correlation with overall survival or quality of life in gynecologic malignancies is unclear. Additionally, time-to-event endpoints like progression-free survival two and time to second subsequent treatment are valuable for assessing disease control in the longer term.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Editorial Material
Oncology
Ainhoa Madariaga, Robert L. Coleman, Antonio Gonzalez Martin
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, Susanna B. Park
Summary: This study aims to provide interpretation guidelines for validated CIPN PROMs, allowing estimation of thresholds to identify clinically relevant symptoms.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2023)
Article
Oncology
Omali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, Sivatharsny Srirangan, Cristina Mapagu, Judy Kirk, Paul R. Harnett, Rosemary L. Balleine, David D. L. Bowtell, Goli Samimi, Alison H. Brand, Deborah J. Marsh, Philip Beale, Lyndal Anderson, Natalie Bouantoun, Pamela Provan, Susan J. Ramus, Anna DeFazio, Michael Friedlander
Summary: The somatic pathogenic variants (PVs) in homologous recombination DNA repair (HR)-related genes in older patients (>=70 years) with high-grade serous ovarian carcinomas (HGSC) are not well-characterized due to low testing rates. However, the overall frequency of somatic PVs in HR-related genes is similar in older and younger patients, highlighting the importance of somatic testing regardless of age.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Antony J. Mersiades, Benjamin J. Solomon, David M. Thomas, Chee K. Lee, Michelle M. Cummins, Lucille Sebastian, Mandy L. Ballinger, Emily Collignon, Olivia M. H. Turnbull, Sonia Yip, Rachael L. Morton, Chris Brown, Patrick J. Wheeler, Malinda Itchins, R. John Simes, Nick Pavlakis
Summary: The ASPiRATION study is a national prospective observational cohort study conducted in Australia that aims to assess the feasibility, clinical value, and economic value of comprehensive genomic profiling (CGP) in newly diagnosed metastatic non-squamous non-small-cell lung cancer. The study will enroll 1000 participants and collect clinical outcome data for a minimum of 2 years. The outcomes of the study will describe the ability of CGP to identify actionable genomic alterations, leading to personalized treatment recommendations, and evaluate the feasibility, cost, and utility of implementing CGP nationally. The study is important in advancing the understanding and application of CGP in lung cancer diagnosis and treatment in Australia.
Article
Oncology
Andres Redondo, Pilar Barretina, Alejandro Perez-Fidalgo, Maria Jesus Rubio, Antonio Gonzalez-Martin
Summary: The objective of this study was to reach a consensus on the management of controversial issues in advanced ovarian cancer. Through the use of nominal group and Delphi techniques, the study successfully achieved consensus on some key issues. The results of this study are significant for addressing controversial issues in the management of advanced ovarian cancer.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)